推荐应用
S100A8 (also known as MRP8, Calgranulin A, and CP-10) and S100A9 (also known as MRP14 and Calgranulin B) are pro-inflammatory members of the S100 family of secreted calcium binding proteins. They are up-regulated in neutrophils and monocytes at sites of inflammation (e.g. psoriasis, rheumatoid arthritis, cardiac ischemia) and are present at elevated concentrations in rheumatoid arthritis synovial fluid. The 10 kDa human S100A8 and 14 kDa S100A9 each contain two EF-hand calcium binding motifs. Human S100A8 shares 57% and 61% amino acid (aa) sequence identity with mouse and rat S100A8, respectively. Human S100A9 shares 57% and 62% amino acid sequence identity with mouse and rat S100A9, respectively. S100A8 and S100A9 are noncovalent homodimers that can also noncovalently heterodimerize; in the presence of calcium and zinc, the homodimer and heterodimers will form tetramers. The heterodimer additionally binds and sequesters manganese, thereby restricting the growth of Mn-dependent bacteria. The S100A8/A9 heterodimer exhibits functions beyond those performed by the individual proteins. These include binding to fatty acids such as arachidonic acid and promoting astrocyte proliferation. S100A8, S100A9, and the heterodimer each promote neutrophil infiltration into sites of inflammation and inflammatory cytokine production by monocytes.
高纯度、高活性、低内毒素、高批间一致性

-25 ~ -15℃保存,收到货之后有效期1年。 复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】GPC3:HCC靶向治疗的核心靶点与药物研发探索
814
2026-04-24
【应用方向】TROP2:从分子机制到实体瘤靶向治疗的研究进展
837
2026-04-24
【应用方向】4-1BB-4-1BBL共刺激轴的T细胞活化机制
510
2026-04-22
【应用方向】TNFR蛋白家族概述
530
2026-04-21
【应用方向】Klotho蛋白:编织生命之线的抗衰老分子
560
2026-04-20
【应用方向】药靶明星 | FGFRs家族蛋白解析
473
2026-04-20
【应用方向】解析Fc受体:抗体药物研发的核心靶点与评价基石
472
2026-04-20
【应用方向】FcγR家族:抗体药物研发的基石与核心靶点
471
2026-04-20
【应用方向】CD47-SIRPα轴研究工具与药物开发应用
452
2026-04-20
【技术讲解】ADC药物研究相关靶点汇总
18940
2025-07-30
【应用方向】抗体药筛选的关键—靶点蛋白
10871
2025-07-09
【技术讲解】重要免疫检查点:PD-1及其配体
20218
2025-07-24
【应用方向】药靶明星|FGFs&FGFRs家族蛋白解析
18527
2025-07-24
【应用方向】热门肿瘤靶点蛋白-EGFR表皮生长因子受体
6326
2025-07-24
【技术讲解】双抗热门靶点-双特异性抗体靶点CD3D&CD3E
14739
2022-09-05





